Skip to main content

Table 4 Distribution of means of variables selected for the final algorithm in test data set using Linear Discriminant Analysis (LDA) model, case study performed in 2019–20 to estimate the incidence of Diabetes Mellitus in France

From: Use of artificial intelligence for public health surveillance: a case study to develop a machine Learning-algorithm to estimate the incidence of diabetes mellitus in France

Ranked ≠ Categories Variables Mean (incident diabetes group) n = 2921 Mean (non- diabetes group) n = 6010 P value (Student’s t-test)
1 AGE Age in years 56.70* 43.69 < 0.0001
2 BIOLOGICAL TESTS Nb. of reimbursement of Alkaline Phosphatase test in last 2 years 0.36* 0.20 < 0.0001
3 BIOLOGICAL TESTS Nb. of reimbursement of Gamma Glutamyle Transferase test in last 2 years 1.05* 0.40 < 0.0001
4 BIOLOGICAL TESTS Nb. of reimbursement of Transaminases (ALAT and ASAT, TGP and TGO) blood test in last 2 years 1.33* 0.63 < 0.0001
5 BIOLOGICAL TESTS Nb. Of reimbursement of Uric Acid (Uricemia) blood test in last 2 years 0.47* 0.22 < 0.0001
6 BIOLOGICAL TESTS Nb. of reimbursement of Glucose blood test in last 2 years 1.29* 0.74 < 0.0001
7 BIOLOGICAL TESTS Nb. Of reimbursement of Creatinine level blood test in last 2 years 1.09* 0.39 < 0.0001
8 BIOLOGICAL TESTS Nb. of reimbursement of Exploration of a Lipid Anomaly (ELA) blood test in last 2 years 1.20* 0.65 < 0.0001
9 BIOLOGICAL TESTS Nb. Of reimbursement of HbA1c tests in last 2 years 0.20* 0.04 < 0.0001
10 BIOLOGICAL TESTS Nb. Of reimbursement of C-Reactive Protein test in last 2 years 1.16* 0.38 < 0.0001
11 DRUGS Nb. Of reimbursement of Proton pump inhibitors drugs in last 2 years 3.67* 0.54 < 0.0001
12 DRUGS Nb. Of reimbursement of other antidiarrheal drugs in last 2 years 0.21* 0.03 < 0.0001
13 DRUGS Nb. of reimbursement of Penicillin with broad spectrum drugs in last 2 years 0.74* 0.23 < 0.0001
14 DRUGS Nb. Of reimbursement of bacterial and viral vaccines, combined (diphtheria-haemophilus influenza B-pertussis-tetanus-hepatitis B-meningococcal A + C) in last 2 years 0.23* 0.13 < 0.0001
15 DRUGS Nb. of reimbursement of Acetic acid derivatives and related substances in last 2 years 0.57* 0.19 < 0.0001
16 DRUGS Nb. of reimbursement of Propionic acid derivatives in last 2 years 1.53* 1.07 < 0.0001
17 DRUGS Nb. of reimbursement of Anilides (Paracetamol) in last 2 years 3.65* 1.69 < 0.0001
18 MEDICAL ACTS Nb. of reimbursement of Fundus examination by biomicroscopy with contact lens in last 2 years 0.30* 0.03 < 0.0001
19 MEDICAL ACTS Nb. of reimbursement of functional examination of the ocular motricity in last 2 years 0.19* 0.08 < 0.0001
20 MEDICAL ACTS Nb. of reimbursement of binocular vision examination in last 2 years 0.32* 0.10 < 0.0001
21 MEDICAL ACTS Nb. of reimbursement of mammography in last 2 years 0.12* 0.10 0.0062
22 MEDICAL ACTS Nb. Of reimbursement of X-ray thorax in the previous 2 years in last 2 years 0.20* 0.07 < 0.0001
23 HOSPITALIZATION Total number of hospitalizations without a procedure (i.e. dialysis, chemotherapy) in last 2 years 0.89* 0.26 < 0.0001
  1. *Highest mean